Gustave Roussy is the first leader cancer-research hospital in Europe and ranked among the top 5 best specialized hospitals in the world. It is a centre for high quality patient care, research and teaching. It is highly-known for the treatment of: skin cancers like melanoma, breast cancer, and lung cancer.

There are 457 beds in Institut Gustave Roussy; Departement Oncologie Medicale.

During the past decade, Institut Gustave Roussy; Departement Oncologie Medicale conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 10 clinical trials were completed, i.e. on average, 90.9% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 4 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Gustave Roussy; Departement Oncologie Medicale" #1 collaborator was "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Frontier Science & Technology Research Foundation, Inc." with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Institut Gustave Roussy; Departement Oncologie Medicale" are "Breast Cancer" (3 trials), "Neoplasms" (3 trials), "Non-Small Cell Lung Cancer" (2 trials), "Renal Cell Carcinoma" (2 trials) and "Adenocarcinoma" (1 trials). Many other conditions were trialed in "Institut Gustave Roussy; Departement Oncologie Medicale" in a lesser frequency.

Most popular intervention types in "Institut Gustave Roussy; Departement Oncologie Medicale" are "Drug" (20 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (5 trials), "Paclitaxel" (5 trials), "Placebo" (5 trials), "Ipatasertib" (4 trials) and "Bevacizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Institut Gustave Roussy; Departement Oncologie Medicale" are 17 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Institut Gustave Roussy; Departement Oncologie Medicale". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Institut Gustave Roussy; Departement Oncologie Medicale, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institut Gustave Roussy; Departement Oncologie Medicale, 6 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".